Overview

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
A Phase 1-2a Study of CXL-1020-01 in Patients with Stable Heart Failure
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborators:
Cardioxyl Pharmaceuticals, Inc
This trial was conducted by the previous sponsor, Cardioxyl